To cite this paper use one of the standards below:
Introduction – Immune-mediated optic neuritis (IMON) is an initial symptom in various demyelinating diseases of the CNS (DDCNS). These conditions exihibit different epidemiological and clinical features in Brazil compared to other Western countries. Understanding the characteristics and frequencies of these underlying conditions in Brazil is crucial for designing public health strategies aimed at early intervention and prevention of more severe outcomes. Objective – To describe the characteristics and frequencies of IMON as the presenting symptom of DDCNS. Methods – We retrospectively selected a cohort of patients with IMON at onset of a DDCNS. IMON-related to multiple sclerosis (MSRON) comprised single isolated optic neuritis (SION), and ON in multiple sclerosis (MSON). Non-related to MS-ON comprised recurring isolated ON (RION), chronic reccurring inflammatory optic neuropathy (CRION), myelin oligodendrocytic glycoprotein-associated ON (MOGAD-ON), neuromyelitis optica ON (NMOSD-ON), ON in association with systemic autoimmune diseases (SAD-ON); parainfectious ON (PION); and vaccine-related ON (VON). Severity of ON was measured by Kurtzke’s Visual Function System Scores (KVFSS). Results – Analysis of 271 IMON patients revealed a mean age of 31.3 ±13 years; with 214 (79%) women. Non-Caucasians comprised 52%, and 13.3% had an associated autoimmune disease. Isolated ON occurred in 70.8%, and bilateral simultaneous ON in 32.5%. The median KVFSS was 2 (range 1-5). MSRON was identified in 101 (37.3%) patients, AQP4-seropositive NMOSD-ON in 36 (13.3%), RION in 26 (9.6%), MOGAD-ON in 14 (5.2%), CRION 2 (0.7%), 7 (2.6%) in ADEM-ON; PION in 7 (2.6%), PV-ON in 14 (5.2%), and SAD in 7 (2.6%) patients. The etiology remained undetermined in 20 (7.4%) patients. Conclusions – Compared to data from other Western populations, in Brazil IMON is more prevalent in non-Caucasians and NMOSD-ON, less so in MS and MOGAD, and is associated with more severe outcomes. These findings underscore the need for tailored healthcare policy in the country.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper